更新于：2024-06-19
FB-101
更新于：2024-06-19
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
关联
1
项与 FB-101 相关的临床试验A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
开始日期2019-10-14 |
申办/合作机构 |
100 项与 FB-101 相关的临床结果
登录后查看更多信息
100 项与 FB-101 相关的转化医学
登录后查看更多信息
100 项与 FB-101 相关的专利（医药）
登录后查看更多信息
4
项与 FB-101 相关的新闻（医药）2023-07-02
·药明康德
▎药明康德内容团队编辑本期看点1. GLP-1/GIP受体双重调节剂CT-388用于治疗超重和肥胖成人的早期临床结果亮眼，每周给药一次，患者的体重在4周内减轻15.4斤。2. 肿瘤免疫治疗新药Galinpepimut-S（GPS）联用PD-1抑制剂纳武利尤单抗治疗恶性胸膜间皮瘤，患者的中位总生存期（OS）约为接受标准治疗的患者的2.5倍。3. 治疗复发或难治性急性髓系白血病的即用型嵌合抗原受体（CAR）自然杀伤（NK）细胞疗法使超过半数患者达到完全缓解（CR）。药明康德内容团队整理CT-388：公布1/2期临床试验数据Carmot Therapeutics公布了其GLP-1/GIP受体双重调节剂CT-388用于治疗超重和肥胖成人的1/2期临床试验的积极数据。结果显示，CT-388的耐受性良好，药代动力学特征支持每周一次的给药频率，最常见的不良事件与胃肠道相关，与肠促胰岛素类别药物一致。在CT-388用药后，患者的体重在4周内减轻了8.4%（15.4斤），同时腰围和臀围缩小，胰岛素敏感性标志物（HOMA-IR）得到改善。该研究的初步概况表明，肥胖患者可能受益最多，因为患者的耐受性更强，体重减轻更多。Galinpepimut-S：公布1期临床试验数据SELLAS Life Sciences Group公司公布了其靶向WT1蛋白的潜在“first-in-class”肿瘤免疫治疗新药Galinpepimut-S联用PD-1抑制剂纳武利尤单抗用于治疗恶性胸膜间皮瘤患者的1期临床数据，这些患者的肿瘤普遍表达WT1。该药由4条多肽链构成，抗原表位多达25个，适用于全球范围内绝大多数人类白细胞组织相容性抗原（HLA）类型，能够激发自身免疫系统对WT1抗原强烈的免疫反应。研究结果显示，该试验达到了安全性和疗效的主要终点，并观察到了联合疗法的临床活性和患者生存率的提高。接受联合疗法的患者的中位OS为70.3周，最后一次随访时有40%的患者存活，而接受标准治疗的复发/难治性患者的中位OS约为28周。根据RECIST标准评估的该联合疗法的疾病控制率（DCR）为30%。此外，没有观察到剂量限制性毒性。NKX101：公布1期临床试验的新数据Nkarta公司更新了其CAR-NK细胞候选疗法NKX101治疗复发或难治性急性髓系白血病患者的临床进展。NKX101是一款同种异体的即用型NK细胞疗法，使用从健康供体中获得的外周血NK细胞，并利用生物工程添加CAR。NKX101的CAR靶向肿瘤表面的NKG2D配体。NKG2D是NK细胞的关键性激活受体，其配体在癌症细胞中过度表达。除了CAR之外，NKX101还表达与细胞膜结合的IL-15，用于增强细胞的持久性和活性。此次更新的数据显示，在使用一周三次的NKX101治疗前采用氟达拉滨/阿糖胞苷清除淋巴细胞，在急性髓系白血病患者（包括一些具有高风险特征的患者）中具有令人鼓舞的抗白血病活性，6名患者中有4名达到CR，其中2名CR患者的微小残留病（MRD）为阴性，1名患者通过额外周期的治疗加深了MRD阴性CR伴不完全的血液恢复（CRi）患者的缓解。此外，NKX101在不同的剂量水平下和淋巴细胞清除疗法中均有良好的耐受性。BB-301：IND申请获得FDA许可BB-301是Benitec Biopharma公司开发的用于治疗眼咽肌营养不良（Oculopharyngeal Muscular Dystrophy）的沉默和取代基因疗法。该疗法利用一种新型的、经过改良的AAV9载体，表达一种独特的、单一的双功能构建体，从而能够促进密码子优化的PABPN1基因和两个针对PABPN1突变体的siRNA的共同表达。这两个siRNA被塑造成microRNA骨架，以抑制有缺陷的PABPN1突变体的表达，同时允许表达经过密码子优化的PABPN1基因，用PABPN1蛋白的功能性版本取代突变体。FPI-1434：公布1期临床试验的中期数据Fusion Pharmaceuticals公司公布了其放射免疫偶联物FPI-1434用于治疗实体肿瘤的1期临床试验的中期数据。FPI-1434结合了抗体的精确定位和发射α粒子的医用同位素的效力，可以特异性地攻击和根除多种肿瘤类型的癌细胞。它的一端能靶向IGF-1R，IGF-1R在癌细胞表面广泛存在，这一抗体能很好地靶向肿瘤，并被内吞入癌细胞内。它的另一端是锕225（225Ac），这种锕的同位素能释放出α粒子，在癌细胞内造成DNA双链的大量断裂，引起癌细胞死亡。此次公布的结果显示，在施用放射性标记的FPI-1434之前预先施用冷抗体（无同位素的裸IGF-1R抗体），有望通过将更多的活性药物推向肿瘤部位而大大增强治疗指数，与只用热剂（单独使用FPI-1434）相比，安全性有所改善。此外，在预先施用冷抗体的情况下，只需注射辐射量的一小部分，就能达到与只用热剂的队列相当的暴露量。结果显示，冷/热方案中15 kBq/kg的药代动力学特征与40 kBq/kg的纯热方案相当，其安全性使其迄今可进行多达5个周期的治疗。此外，两名此前接受过大量治疗的患者在接受了3个和5个周期的治疗后实现了持久的疾病稳定。该公司正在继续评估队列2中更高剂量水平的冷/热方案，预计将在2023年年底左右公布这些结果。FB101：公布1期临床试验数据Freya Biosciences公司公布了其在研阴道微生物免疫疗法FB101用于治疗无症状阴道生态失调女性的1期临床试验的积极顶线结果。结果表明，连续三天在阴道内使用FB101后，患者阴道菌群失调的问题得到了解决，菌群从失调状态迅速转变为以乳酸菌为主的阴道微生物群，并保持了8周以上。此外，一半的妇女建立了FB101乳酸菌的定植（由菌种水平的移植分析确定），并观察到了炎症标志物的变化。该公司后续计划探索FB101用于提高体外受精的成功率并改善生育结果。大家都在看▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息参考资料（可上下滑动查看）[1] Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy. Retrieved June 30, 2023, from https://www.globenewswire.com/news-release/2023/06/26/2694388/0/en/Benitec-Biopharma-Receives-FDA-Clearance-of-the-IND-for-BB-301-for-the-Treatment-of-Oculopharyngeal-Muscular-Dystrophy.html[2] portage biotech announces first patient dosed in phase 1a trial of port-6 in select solid tumors. Retrieved June 30, 2023, from https://ir.portagebiotech.com/news-releases/news-release-details/portage-biotech-announces-first-patient-dosed-phase-1a-trial[3] cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular Prosthetic for Cystic Fibrosis. Retrieved June 30, 2023, from https://www.prnewswire.com/news-releases/cystetic-medicines-initiates-phase-1-clinical-trial-of-a-molecular-prosthetic-for-cystic-fibrosis-301863104.html[4] Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease. Retrieved June 30, 2023, from https://www.freeline.life/investors/newsroom/freeline-announces-first-patient-dosed-with-its-novel-gene-therapy-candidate-for-gaucher-disease-and-unveils-research-program-in-gba1-linked-parkinson-s-disease/[5] Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701. Retrieved June 30, 2023, from https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-announces-dosing-first-infant-enpp1-deficiency[6] IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate. Retrieved June 30, 2023, from https://www.accesswire.com/763800/IAVI-Starts-First-in-Human-Phase-I-Clinical-Trial-of-Single-Dose-Sudan-Virus-Vaccine-Candidate[7] Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) . Retrieved June 30, 2023, from https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-first-patient-dosed-in-second-cohort-of-phase-1b-multiple-ascending-dose-mad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-301863810.html[8] HARPOON THERAPEUTICS ANNOUNCES COMPLETION OF PLANNED PATIENT ENROLLMENT IN PHASE 1 STUDY OF HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. Retrieved June 30, 2023, from https://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-announces-completion-planned-patient[9] First-in-Man trial for Lobe's proprietary stabilized psilocin analogue All subjects dosed with no significant adverse events to date. Retrieved June 30, 2023, from https://s3.amazonaws.com/b2icontent.irpass.cc/2565/rl119662.pdf[10] Microba Commences Phase I Clinical Trial for IBD Therapeutic. Retrieved June 30, 2023, from https://www.businesswire.com/news/home/20230627143323/en/[11] Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors. Retrieved June 30, 2023, from https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ct-0508-in-combination-with-keytruda-pembrolizumab-in-patients-with-her2-overexpressing-solid-tumors-301865175.html[12] Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S. Retrieved June 30, 2023, from https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-first-patient-enrolled-in-phase-1-clinical-trial-of-cd19-car-t-cell-therapy-for-lupus-nephritis-in-the-us-301866433.html[13] Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions. Retrieved June 30, 2023, from https://carmot.us/carmot-therapeutics-highlights-clinical-data-from-its-pipeline-of-treatments-for-obesity-and-diabetes-at-the-83rd-american-diabetes-association-scientific-sessions/[14] Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R. Retrieved June 30, 2023, from https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-interim-data-from-phase-1-trial-of-fpi-1434-in-patients-with-solid-tumors-expressing-igf-1r-301862952.html[15] Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis. Retrieved June 30, 2023, from https://www.businesswire.com/news/home/20230627892527/en/[16] NKARTA UPDATES CLINICAL PROGRESS OF CAR-NK CELL THERAPY NKX101 FOR PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. Retrieved June 30, 2023, from https://ir.nkartatx.com/news-releases/news-release-details/nkarta-updates-clinical-progress-car-nk-cell-therapy-nkx101[17] SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma. Retrieved June 30, 2023, from https://www.globenewswire.com/news-release/2023/06/28/2696184/0/en/SELLAS-Life-Sciences-Reports-Positive-Data-in-Completed-Phase-1-Study-of-Galinpepimut-S-Combined-with-Opdivo-in-Advanced-Malignant-Pleural-Mesothelioma.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新
免疫疗法细胞疗法临床结果临床1期
2023-06-27
FB101 will advance into clinical testing for patients undergoing IVF procedures to see whether it can boost fertility treatment outcomes and success rates.
Women’s health biotech Freya Biosciences will advance an immunotherapy for a bacterial imbalance in the vagina into patients undergoing in vitro fertilization after early-stage results showed resolution of the condition.
Freya’s lead compound, FB101, was administered over three consecutive days in a phase 1 study of women with asymptomatic vaginal tract dysbiosis. The condition is characterized by the loss of dominance of the Lactobacillus bacteria in the vagina and an increase in microbiota diversity. This can lead to various diseases, including bacterial vaginitis, vulvovaginal candidiasis, human papillomavirus, herpes simplex virus-2 and many more, which take advantage of the less protective environment.
The imbalance can also lead to miscarriages, preterm birth or infertility—and that’s where Freya is hoping to make a difference.
Freya was testing to see whether FB101 could resolve the dysbiosis and reestablish Lactobacillus, keeping the bacteria sustained over eight weeks. The therapy did just that, but also showed that the FB101 Lactobacilli species was established in half of the women. Freya also noted a change in inflammatory markers.
Now, FB101 will advance into clinical testing for patients undergoing IVF procedures to see whether it can boost fertility treatment outcomes and success rates. Asymptomatic vaginal dysbiosis is often flagged in women undergoing IVF and can impact treatment success, Freya said in a Tuesday release.
The study was conducted in Europe in conjunction with a cohort at Boston IVF.
临床1期临床结果免疫疗法
2023-04-20
Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important dopamine chemical. Studies have shown that symptoms of Parkinson's develop in patients with an 80% or greater loss of dopamine-producing cells in the substantia nigra. Most Parkinson's patients are treated with medications to relieve the symptoms of the disease. These medications work by stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or by inhibiting some of the acetylcholine that is produced (anticholinergic medications), therefore restoring the balance between the chemicals in the brain.
LAS VEGAS, April 19, 2023 /PRNewswire/ -- DelveInsight's
'
Parkinson's Disease Pipeline Insight – 2023
' report provides comprehensive global coverage of available, marketed, and pipeline Parkinson's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Parkinson's disease pipeline domain.
Key Takeaways from the Parkinson's Disease Pipeline Report
DelveInsight's Parkinson's disease pipeline report depicts a robust space with
120+ active players working to develop
140+ pipeline therapies for Parkinson's disease treatment.
Key Parkinson's disease companies such as
Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others are evaluating new Parkinson's disease drugs to improve the treatment landscape.
Promising Parkinson's disease pipeline therapies in various stages of development include
Tavapadon, IkT-148009, NLY01, PT320, BIIB122, Prasinezumab, KDT-3594, AAV2-GDN, AKST4290, anle138b, ITI-214, NTCELL, Buntanetap, ANAVEX2-73, ATH-1017, NE3107, MEDI1341, AZD0328, Liraglutide, UB-312, LY03003, FB-101, AV-101, ABBV-951, NYX-458, DSP-9632P, Valiloxybate, SER-214, UCB7853, TAK-071, XC130-A10H, K0706, Talineuren, Pirepemat, Lu AF28996, WD-1603, CVN424, CST-103, NBTX-001, MSK-DA01, Aadipose-Derived Mesenchymal Stem Cells, ND0612, P2B001, 1ST-103, 1ST-105, and others.
In January 2023, Neurocrine Biosciences and Voyager Therapeutics announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases. The collaboration includes Voyager's preclinical, intravenously administered GBA1 gene therapy program for Parkinson's and other GBA1-mediated diseases, combining a GBA1 gene replacement payload with novel capsids from Voyager's TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform. In addition, Neurocrine Biosciences and Voyager have agreed to collaborate on three new gene therapy programs directed to rare CNS targets, each also leveraging Voyager's novel TRACER capsids.
In October 2022, Biogen Inc. and Denali Therapeutics Inc. announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122 (DNL151), as compared to placebo in approximately 400 participants with Parkinson's disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene.
In September 2022, Neuron23, Inc. an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN announced a collaboration to develop a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease.
Request a sample and discover the recent advances in Parkinson's disease drug treatment @
Parkinson's Disease Pipeline Report
The Parkinson's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Parkinson's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Parkinson's disease clinical trial landscape.
Parkinson's Disease Overview
Parkinson's disease is a progressive disorder caused by nerve cell degeneration in the substantia nigra, a part of the brain that controls movement. These nerve cells die or become impaired, losing the ability to produce dopamine, an important chemical. According to research, symptoms of Parkinson's disease develop in patients who have an 80% or greater loss of dopamine-producing cells in the substantia nigra.
Dopamine works typically in tandem with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in the movement. This balance is disrupted when there is insufficient dopamine, resulting in tremors (trembling in the hands, arms, legs, and jaw), rigidity (stiffness of the limbs), slowness of movement, and impaired balance and coordination - the hallmark Parkinson's disease symptoms.
The cause of Parkinson's disease is largely unknown. However, as potential causes of the disease, theories involving oxidative damage, environmental toxins, genetic factors, and accelerated aging have been discussed. The majority of Parkinson's patients are given medications to alleviate their symptoms. These Parkinson's disease medications work by either stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or inhibiting some of the acetylcholine produced (anticholinergic medications), restoring the balance of chemicals in the brain.
Find out more about drugs for Parkinson's disease @
New Parkinson's Disease Drugs
A snapshot of the Parkinson's Disease Pipeline Drugs mentioned in the report:
Learn more about the emerging Parkinson's disease pipeline therapies @
Parkinson's Disease Clinical Trials
Parkinson's Disease Therapeutics Assessment
The
Parkinson's disease pipeline report proffers an integral view of Parkinson's disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Parkinson's Disease Pipeline Report
Coverage: Global
Parkinson's Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Parkinson's Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Parkinson's Disease Therapeutics Assessment
By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
Parkinson's Disease Therapeutics Assessment
By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
Parkinson's Disease Therapeutics Assessment
By Mechanism of Action: Dopamine D1 receptor agonists, Dopamine D5 receptor agonists, Bcr-abl tyrosine kinase inhibitors, Glucagon like peptide 1 receptor agonists, LRRK2 protein inhibitors, Alpha-synuclein inhibitors, Dopamine receptor agonists
Key Parkinson's Disease Companies: Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
Key Parkinson's Disease Pipeline Therapies: Tavapadon, IkT-148009, NLY01, PT320, BIIB122, Prasinezumab, KDT-3594, AAV2-GDN, AKST4290, anle138b, ITI-214, NTCELL, Buntanetap, ANAVEX2-73, ATH-1017, NE3107, MEDI1341, AZD0328, Liraglutide, UB-312, LY03003, FB-101, AV-101, ABBV-951, NYX-458, DSP-9632P, Valiloxybate, SER-214, UCB7853, TAK-071, XC130-A10H, K0706, Talineuren, Pirepemat, Lu AF28996, WD-1603, CVN424, CST-103, NBTX-001, MSK-DA01, Aadipose-Derived Mesenchymal Stem Cells, ND0612, P2B001, and others.
Dive deep into rich insights for new drugs for Parkinson's disease treatment; visit @
Parkinson's Disease Medications
Table of Contents
For further information on the Parkinson's disease pipeline therapeutics, reach out @
Parkinson's Disease Drug Treatment
Related Reports
Parkinson's Disease Market
Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including
Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, among others.
Parkinson's Disease Epidemiology Forecast
Parkinson's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Parkinson's disease epidemiology trends.
Dementia with Lewy Bodies Pipeline
Dementia with Lewy Bodies Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dementia with Lewy bodies companies, including
Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., among others.
Dementia with Lewy Bodies Epidemiology Forecast
Dementia with Lewy Bodies Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted dementia with Lewy bodies epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Dementia Market
Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies, including
Hoffmann-La Roche, Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Merck and Co., Inc., Novartis, among others.
Parkinson's Disease-Related Dementia Market
Parkinson's Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease-related dementia companies, including
AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market
| Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
临床3期
100 项与 FB-101 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 帕金森病 | 临床1期 | 美国 | 2019-10-14 | |
| 肌萎缩侧索硬化 | 临床1期 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | - | 獵觸壓衊艱窪獵獵選襯(鏇獵鑰鬱範襯壓範鑰繭) = The SAD portion of the Phase I clinical trial of FB-101 was completed in Baltimore, MD, USA, and demonstrated that oral administration of FB-101 was well-tolerated across all cohorts with favorable safety results. No clinically significant findings were observed on safety measures including laboratory findings, vital signs, and ECGs at any dose. 餘憲醖艱醖鏇夢簾願構 (壓蓋繭鏇衊糧糧夢鏇夢 ) | 积极 | 2022-10-18 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用